Researchers at the University of California, Davis, have created a technology that uses engineered polynucleotides to deliver both an antigen and an enzyme that breaks down amino acids. This approach is designed to boost long-lasting memory T-cell responses, providing stronger protection against infectious diseases and cancer.

Brief description not available

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed a peptide nucleic acid-based system enabling precise and customizable delivery of antigens, adjuvants, and targeting molecules for improved cancer immunotherapy.

Brief description not available

Researchers at the University of California, Davis have developed an advancement in the field of healthcare technology, specifically in the development and application of silyl lipids for RNA vaccines.

Progressive Multifocal Leukoencephalopathy (PML) is a devastating and often fatal demyelinating disease of the central nervous system caused by the reactivation of the JC virus (JCV). In immunocompromised patients, the absence of effective T cell surveillance allows the virus to infect and lyse oligodendrocytes, leading to irreversible neurological damage. UC Berkeley researchers have developed a method for discovering and engineering antigen-specific T cell receptors (TCRs) that specifically target JCV.

Researchers at the University of California, Davis have developed a vaccine platform utilizing non-replicating, metabolically active Cyborg Bacterial Pathogens to combat multi-antibiotic-resistant bacteria.

Chinese hamster ovary (CHO) cells are a family of immortalized cells derived from the epithelial cells of the ovary of the Chinese hamster. They are among the most widely used cell systems in cell biology. The cell line is frequently used in biological and medical research. It’s specifically used in the production of recombinant therapeutic proteins. Essentially, the CHO cell is used as a “factory cell,” meaning it can be programmed to produce therapeutic proteins, including vaccines and antibodies.Recombinant protein expression has been used in the development of biologics for many applications including therapeutics and vaccines.  However, one challenge in the development of biologics is the unintended proteolysis associated of expressed recombinant proteins in CHO cells. One example of a biologic that faces supoptimal expression in CHO cells is the HIV envelope glycoprotein, gp120, which is one of the main targets for neutralizing antibodies in HIV infection and a prime candidate for component of an HIV vaccine. When expressed in CHO cells, gp120 undergoes proteolytic clipping by a serine protease at an epitope recognized by neutralizing antibodies. Essentially, the cells produce an enzyme that cuts gp120 into pieces. This proteolysis alters gp120 to the point where it is unrecognizable by the immune system and renders it non-immunogenic. This issue appears frequently with CHO expression of envelope proteins from clade B HIV. Clade B is the most common genetic subtype present in the US and Europe. While this issue has been observed and attributed to CHO cells, it was previously unknown which enzyme was responsible. Without knowledge of the enzyme responsible, the solutions were based on modifying the protein sequence or adjusting the conditions of production, both of which are suboptimal. 

This technology offers a revolutionary approach to point-of-care diagnosis and large-scale health surveillance by enabling portable, high-accuracy detection of proteins, bioparticles, and cells.

This technology represents a pioneering approach to vaccine development, focusing on encapsulated adjuvants and antigens to enhance efficacy while minimizing side effects.

A cutting-edge vaccine delivery platform that enhances tumor treatment by co-delivering MHC class I and II restricted antigens.

Researchers at UCI have discovered the tertiary structure of the Chlamydia major outer membrane protein (MOMP). Despite historical challenges in formulating an effective vaccine, recent advancements in understanding MOMP's structure offer new pathways for vaccine development against urogenital and ocular infections caused by C. trachomatis.

This invention addresses the challenge of delivering macromolecules and other therapeutic cargo into the cell's cytoplasm by overcoming the endosomal membrane barrier. The innovation, developed by UC Berkeley researchers, involves improved versions of the ZF5.3 peptide. These improved peptide variants significantly enhance the efficiency of endosomal escape. This advancement provides a more effective and reliable method for intracellular delivery compared to existing alternatives, which often suffer from low efficiency or significant toxicity.

This technology introduces a novel vaccine delivery system using thermosensitive hydrogels for sustained antigen release, aiming to improve immune response durability and breadth.

Researchers at the University of California, Davis have developed advanced compounds targeting neuraminidase activity to combat viral infections and understand cellular mechanisms.

Brief description not available

Researchers at the University of California, Davis have developed an approach to elicit powerful immune responses by engineering the binding capabilities of single chain trimer (SCT) proteins to CD8.

Researchers from UC San Diego developed an invention that enables protein expression to be upregulated using specific proteins and/or peptide sequences derived from SARS-CoV-2 proteins that are engineered to recognize specific mRNA transcripts by fusion to RNA-targeting modules such as CRISPR/Cas systems. They anticipate that these proteins can be fused or tethered to any engineered RNA-targeting moiety/module such as PUF/Pum, and pentatricopeptide proteins.

α-Fetoprotein (AFP) is a fetal glycoprotein produced by the majority of human hepatocellular carcinoma tumors and other tumor types. Delineating differences between fetal 'normal' AFP (nAFP) and tumor-derived AFP (tAFP), investigators at UCSF and the Parker Institute for Cancer Immunotherapy have uncovered a novel role for tAFP in altering metabolism via lipid-binding partners. They have developed a pharmaceutical composition comprising AFP bound by a fatty acid which, depending on the fatty acid used, can have an immunosuppressive effect allowing for the treatment of inflammatory diseases.  AFP bound to other fatty acids can eliminate the immune suppressive impact and have a neutral effect which allows for the development of dendritic cell (DC) vaccines presenting AFP epitopes which could be used to treat and prevent tumor AFP-expressing cancers.  

Poly (ethylene glycol) (PEG) is a widely used polymer in a variety of consumer products and in medicine. PEG is viewed as being well-tolerated, but previous studies have identified anti-PEG antibodies and pseudoallergic reactions in certain individuals. The increased use of lipid nanoparticles (LNPs) as contrast agents or in drug delivery, along with the introduction of mRNA vaccines encapsulated in PEGylated lipid nanoparticles is a concern.  UC Berkeley researchers have created Lipid nanoparticles with new polymers that do not generate PEG antibodies. Cell and animal work demonstrate that these new polymers deliver mRNA efficiently in vitro and in vivo.

Researchers at UC Irvine have identified and tested a molecular target that regulates T cell function during chronic viral infection and cancer. The molecular target is one of the high mobility group proteins (HMGB2). HMGB2 is a DNA binding protein that regulates transcriptional processes, meaning that its modulation will have profound effects on T cell differentiation and ultimate function by altering the expression of many genes.

Vaccine design is at the forefront of therapeutic development. Candidate proteins for recombinant vaccine design are expressed as soluble proteins lacking the native transmembrane domain. These proteins are often fused with multimerization domains to stabilize the native oligomeric state of the candidate protein. However, these multimerization domains can elicit off-target immune responses, raising concerns regarding risks of unintended immunogenicity. Thus, there is a need to eliminate potential off-target effects of recombinant vaccine candidates that contain multimerization domains such as the foldon domain.

Researchers at the University of California, Davis have developed a method to stop bacterial growth while maintaining desirable metabolic functions for therapeutic and biotechnological applications.